BenzingaAugust 13, 2026 at 5:32 AM NY2 Months Ago
Wells Fargo Maintains Overweight on Definium Therapeutics, Raises Price Target to $72
Wells Fargo analyst Benjamin Burnett maintains Definium Therapeutics (NASDAQ:DFTX) with a Overweight and raises the price target from $68 to $72.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
